ENDS
Enquiries
Hikma Pharmaceuticals PLC
+44 (0)20 7399 2760
Susan Ringdal, Investor Relations Director
Financial Dynamics
+44 (0)20 7831 3113
Ben Atwell/Julia Phillips/Jonathan Birt/Matthew Cole
About West-Ward Pharmaceuticals
West-Ward Pharmaceuticals, the US agent for and wholly-owned subsidiary of Hikma
Pharmaceuticals PLC, is one of the top 15 generic prescription medication
providers in the US, providing quality pharmaceuticals to a growing number of
chain stores, wholesalers, distributors, health systems and government agencies.
Based in Eatontown, New Jersey, West-Ward has over 50 years' manufacturing
experience and an exemplary FDA track record, and is fast becoming the generic
pharmaceutical company of choice. For more information, please visit
www.west-ward.com.
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products. Hikma's operations are conducted
through three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region, where it is a
market leader, the United States and Europe. In 2009, Hikma achieved revenues
of $637 million and profit attributable to shareholders of $78
million. For news and other information, please visit www.hikma.com.
Forward looking statements
Certain statements in this announcement are forward-looking statements - using
words such as "intends", "believes", anticipates" and "expects". Where
included, these have been made by the Directors in good faith based on the
information available to them up to the time of their approval of this
announcement. By their nature, forward-looking statements are based on
assumptions and involve inherent risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by the
forward-looking statements, and should be treated with caution. These risks,
uncertainties or assumptions could adversely affect the outcome and financial
effects of the plans and events described in this announcement. Forward-looking
statements contained in this announcement regarding past trends or activities
should not be taken as a representation that such trends or activities will
continue in the future. You should not place undue reliance on forward-looking
statements, which speak as only of the date of the approval of this
announcement.
Except as required by law, the Company is under no obligation to update or keep
current the forward-looking statements contained in this announcement or to
correct any inaccuracies which may become apparent in such forward-looking
statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQUWUNRRKARUAA